Use of dipeptidyl peptidase IV inhibitor in the comprehensive management of type 2 diabetes mellitus in Chinese population
2018
Currently, China still faces tremendous challenges
in the field of diabetes treatment and control, and new treatments
are needed for comprehensive management of patients with type 2 diabetes
mellitus. Dipeptidyl peptidase IV (DPP-4) inhibitors can improve islet
cell function, promote the secretion of insulin and inhibit the secretion
of glucagon, without increased risks of hypoglycemia and weight gain.
DPP-4 inhibitors, regardless of monotherapy or in combination with
other anti-hyperglycemic medication or insulin, can effectively reduce
glycated hemoglobin (HbA1c), fasting and postprandial blood glucose
in poorly controlled type 2 diabetes. The early combination of DPP-4
inhibitor with metformin, by complementing each other in the therapeutic
mechanism, is an ideal therapeutic strategy for diabetes treatment.
This article briefly reviews the efficacy and safety of DPP-4 inhibitors
in the treatment of type 2 diabetes in Chinese population.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI